Skip to main content
SpringerLink
Log in

Opinion and Evidence in Neurology and Psychiatry

  • From the World Literature
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. * The researchers were affiliated with Pfizer.

  2. Response equals a decrease of ≥50% from baseline in HARS score.

  3. * The study received financial support from Johnson & Johnson Pharmaceutical Research and Development, Belgium.

  4. Costs (2001 values) were those associated with drug acquisition, inpatient, outpatient and emergency department visits, diagnostic tests and procedures, and general practitioner, nurse, social worker and psychiatrist/psychologist contacts. Costs and benefits were discounted at 3% per annum.

  5. * This study was supported by Johnson & Johnson Pharmaceutical Research & Development.

  6. * This study was supported in part by AstraZeneca GmbH, Germany.

  7. * Lamotrigine dosage was 100–400 mg/day depending on clinical response.

  8. Lithium dosage was titrated to serum levels of 0.8–1.1 mEq/L.

  9. This study was supported by Abbott Laboratories.

  10. * The study was funded by McNeil Consumer & Specialty Pharmaceuticals, USA.

Reference

  • Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003 Mar; 160: 533–40

    Article  PubMed  Google Scholar 

Reference

  • Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003; 64(Suppl. 3): 28–35

    PubMed  CAS  Google Scholar 

Reference

  • Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: cost-effectiveness in refractory epilepsy. Clin Drug Invest 2003; 23(4): 225–32

    Article  CAS  Google Scholar 

Reference

  • Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 Mar; 107: 165–75

    Article  PubMed  CAS  Google Scholar 

Reference

  • Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. III: initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003 Mar; 60: 379–85

    Google Scholar 

Reference

  • Sørensen HJ, Mortensen EL, Reinisch JM, et al. Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? Am J Psychiatry 2003 Mar; 160: 464–8

    Article  PubMed  Google Scholar 

Reference

  • Neuhauser H, Radtke A, von Brevern M, et al. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003 Mar 11; 60: 882–3

    Article  PubMed  CAS  Google Scholar 

Reference

  • MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antide-pressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003 May 10; 326: 1014–7

    Article  PubMed  CAS  Google Scholar 

Reference

  • Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 Apr; 60: 392–400

    Article  PubMed  CAS  Google Scholar 

Reference

  • Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003 Apr; 42: 424–33

    Article  PubMed  Google Scholar 

Reference

  • Consumers’ Association. MMR vaccine: how effective and how safe? Drug Ther Bull 2003 Apr; 41: 25–9

    Article  Google Scholar 

Reference

  • Liu D, Guo H, Griffin JH, et al. Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation 2003 Apr 8; 107: 1791–6

    Article  PubMed  Google Scholar 

Reference

  • Berthier ML, Hinojosa J, del Carmen Martin M, et al. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003 Apr 8; 60: 1218–9

    Article  PubMed  Google Scholar 

Reference

  • Shulman Kl, Rochon P, Sykora K, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003 May 3; 326: 960–1

    Article  PubMed  Google Scholar 

Reference

  • Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003 May 10; 361: 1581–9

    Article  PubMed  CAS  Google Scholar 

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Neurology and Psychiatry. CNS Drugs 17, 601–608 (2003). https://doi.org/10.2165/00023210-200317080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317080-00005

Search

Navigation